One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk
MarkTrinderMScabKaavyaParuchuriMDbcdeSaraHaidermotaBSbcRachelBernardoBScdSeyedeh MaryamZekavatBSbfThomasGillilandMDbcdeJamesJanuzziJr.MDdePradeepNatarajanMD, MMScbcde
doi : 10.1016/j.jacc.2021.11.055
Volume 79, Issue 7, 22 February 2022, Pages 617-628
When indicated, guidelines recommend measurement of lipoprotein(a) for cardiovascular risk assessment. However, temporal variability in lipoprotein(a) is not well understood, and it is unclear if repeat testing may help refine risk prediction of coronary artery disease (CAD).
Measurement of Lipoprotein(a): A Once in a Lifetime Opportunity
Santica M.MarcovinaScD, PhDaMichael D.ShapiroDO, MCRb
doi : 10.1016/j.jacc.2021.11.053
Volume 79, Issue 7, 22 February 2022, Pages 629-631
Splenic Marginal Zone B Lymphocytes Regulate Cardiac Remodeling After Acute Myocardial Infarction in Mice
YanyiSunPhDaCristinaPintoPhDaStéphaneCamusPhDaVincentDuvalMScaPaulAlayracMScaIvanaZlatanovaPhDaXavierLoyerPhDaJoseVilarPhDaMathildeLemitreBScaAngéliqueLevoyePhDabMeritxellNusPhDcHafidAit-OufellaMD, PhDaZiadMallatMD, PhDacJean-SébastienSilvestrePhDa
doi : 10.1016/j.jacc.2021.11.051
Volume 79, Issue 7, 22 February 2022, Pages 632-647
Mature B lymphocytes alter the recovery of cardiac function after acute myocardial infarction (MI) in mice. Follicular B cells and marginal zone B (MZB) cells are spatially distinct mature B-cell populations in the spleen, and they exert specific functional properties. microRNA-21 (miR21)/hypoxia-inducible factor-α (HIF-α)–related pathways have been shown to govern B-cell functions.
Immuno-Modulation to Treat Common Cardiovascular Diseases: Moving From Sledgehammer to Precision Therapeutics
Jason C.KovacicMBBS, PhDabcLisardoBoscáPhDd
doi : 10.1016/j.jacc.2021.12.007
Volume 79, Issue 7, 22 February 2022, Pages 648-650
Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial
RoxySeniorMD, DMaHarmony R.ReynoldsMDbJames K.MinMDcDaniel S.BermanMDdMichael H.PicardMDefBernard R.ChaitmanMDgLeslee J.ShawPhDcCourtney B.PageMAhSajeev C.GovindanMDiJoseLopez-SendonMDjJesusPeteiroMDkGurpreet S.WanderMDlJaroslawDrozdzMDmJoseMarin-NetoMDnJoseph B.SelvanayagamMBBS, DphiloJonathan D.NewmanMD, MPHbChristopheThuaireMDpJohannChristopherMD, MBBS, DNBq…Judith S.HochmanMDb
doi : 10.1016/j.jacc.2021.11.052
Volume 79, Issue 7, 22 February 2022, Pages 651-661
Detection of ≥50% diameter stenosis left main coronary artery disease (LMD) has prognostic and therapeutic implications. Noninvasive stress imaging or an exercise tolerance test (ETT) are the most common methods to detect obstructive coronary artery disease, though stress test markers of LMD remain ill-defined.
Predicting Left Main Coronary Artery Stenosis Without Imaging: Are We There Yet?
Waleed T.KayaniMDaUmairKhalidMDabMahboobAlamMDa
doi : 10.1016/j.jacc.2021.11.054
Volume 79, Issue 7, 22 February 2022, Pages 662-664
Myocardial Fibrosis Predicts Ventricular Arrhythmias and Sudden Death After Cardiac Electronic Device Implantation
FranciscoLeyvaMDaAbbasinZegardMBChBabOsitaOkaforMBChBabPaulFoleyMDcFrazUmarMBChBdRobin J.TaylorMDeHowardMarshallMDbBertholdStegemannPhDaWilliamMoodyMDbRichard P.SteedsPhDbBrian P.HallidayMDfDaniel J.HammersleyMBChBfRichard E.JonesMBChBfSanjay K.PrasadMDfTianQiuPhDb
doi : 10.1016/j.jacc.2021.11.050
Volume 79, Issue 7, 22 February 2022, Pages 665-678
Increasing evidence supports a link between myocardial fibrosis (MF) and ventricular arrhythmias.
Defibrillator or No Defibrillator With CRT: That Is the Question for CMR
Christopher M.KramerMDabKenneth C.BilchickMDa
doi : 10.1016/j.jacc.2021.12.008
Volume 79, Issue 7, 22 February 2022, Pages 679-681
Autonomic Neuromodulation for Atrial Fibrillation Following Cardiac Surgery: JACC Review Topic of the Week
StefanosZafeiropoulosMD, MScabIoannisDoundoulakisMD, MSccdIoannis T.FarmakisMD, MSceSantiagoMiyaraMDabDimitriosGiannisMD, MScbGeorgeGiannakoulasMD, PhDeDimitrisTsiachrisMD, PhDdRamanMitraMD, PhDfNicholas T.SkipitarisMDgStavros E.MountantonakisMDgStavrosStavrakisMD, PhDhStavrosZanosMD, PhDb
doi : 10.1016/j.jacc.2021.12.010
Volume 79, Issue 7, 22 February 2022, Pages 682-694
Autonomic neuromodulation therapies (ANMTs) (ie, ganglionated plexus ablation, epicardial injections for temporary neurotoxicity, low-level vagus nerve stimulation [LL-VNS], stellate ganglion block, baroreceptor stimulation, spinal cord stimulation, and renal nerve denervation) constitute an emerging therapeutic approach for arrhythmias. Very little is known about ANMTs’ preventive potential for postoperative atrial fibrillation (POAF) after cardiac surgery. The purpose of this review is to summarize and critically appraise the currently available evidence. Herein, the authors conducted a systematic review of 922 articles that yielded 7 randomized controlled trials. In the meta-analysis, ANMTs reduced POAF incidence (OR: 0.37; 95% CI: 0.25 to 0.55) and burden (mean difference [MD]: −3.51 hours; 95% CI: −6.64 to −0.38 hours), length of stay (MD: −0.82 days; 95% CI: −1.59 to −0.04 days), and interleukin-6 (MD: −79.92 pg/mL; 95% CI: −151.12 to −8.33 pg/mL), mainly attributed to LL-VNS and epicardial injections. Moving forward, these findings establish a base for future larger and comparative trials with ANMTs, to optimize and expand their use.
Editor-in-Chief’s Top Picks From 2021
ValentinFusterMD, PhD
doi : 10.1016/j.jacc.2022.01.004
Volume 79, Issue 7, 22 February 2022, Pages 695-753
Temporary Spinal Cord Stimulation to Prevent Postcardiac Surgery Atrial Fibrillation: 30-Day Safety and Efficacy Outcomes
AlexanderRomanovMD, PhDVladimirLomivorotovMD, PhDAlexanderChernyavskiyMD, PhDVladimirMurtazinMDElenaKliverMD, PhDDmitryPonomarevMDIgorMikheenkoMDAlexanderYakovlevMDMarinaYakovlevaMDJonathan S.SteinbergMD
doi : 10.1016/j.jacc.2021.08.078
Volume 79, Issue 7, 22 February 2022, Pages 754-756
Reduction in Risk of Disease Progression With Triple Therapy: Is It True for All?
Robert D.RossMD
doi : 10.1016/j.jacc.2021.11.049
Volume 79, Issue 7, 22 February 2022, Page e175
Reply: Reduction in Risk of Disease Progression With Triple Therapy: Is it True for All?
Kelly M.ChinMDMartinDoelbergPhDNicolasMartinMScLoïcPerchenetPhDNazzarenoGalieMD
doi : 10.1016/j.jacc.2021.12.006
Volume 79, Issue 7, 22 February 2022, Page e177
